4883
Modalis Therapeutics Corporation
モダリス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
1,100
Dec 2022
40,500
Dec 2023
-
Dec 2024
-
Dec 2025
-
Operating profit(thousand JPY)
Dec 2021
-1,239,444
Dec 2022
-2,063,194
Dec 2023
-2,370,666
Dec 2024
-1,337,650
Dec 2025
-2,211,801
Operating profit margin(%)
Dec 2021
-112,676.73
Dec 2022
-5,094.31
Dec 2023
-
Dec 2024
-
Dec 2025
-
Profit before tax(thousand JPY)
Dec 2021
-745,417
Dec 2022
-2,707,031
Dec 2023
-2,390,607
Dec 2024
-1,316,929
Dec 2025
-2,151,170
Profit(thousand JPY)
Dec 2021
-738,956
Dec 2022
-2,702,709
Dec 2023
-2,391,821
Dec 2024
-1,317,894
Dec 2025
-2,152,710
Total assets(thousand JPY)
Dec 2021
6,069,137
Dec 2022
3,129,833
Dec 2023
2,025,925
Dec 2024
3,691,549
Dec 2025
2,964,248
Cash and cash equivalents(thousand JPY)
Dec 2021
4,936,193
Dec 2022
2,933,162
Dec 2023
1,883,437
Dec 2024
3,575,277
Dec 2025
2,812,367
Cash flows from operating activities(thousand JPY)
Dec 2021
-747,466
Dec 2022
-1,895,773
Dec 2023
-2,254,466
Dec 2024
-1,432,005
Dec 2025
-2,118,409
Cash flows from investing activities(thousand JPY)
Dec 2021
171,563
Dec 2022
-185,719
Dec 2023
-39,699
Dec 2024
-188
Dec 2025
-2,571
Cash flows from financing activities(thousand JPY)
Dec 2021
72,633
Dec 2022
63,683
Dec 2023
1,216,451
Dec 2024
3,044,985
Dec 2025
1,351,037
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
91.4
Dec 2022
93.4
Dec 2023
66.8
Dec 2024
95.5
Dec 2025
93
Earnings per share(JPY per share)
Dec 2021
-25.7
Dec 2022
-92.85
Dec 2023
-77.24
Dec 2024
-28.57
Dec 2025
-27.86
Net assets per share(JPY per share)
Dec 2021
191.57
Dec 2022
99.53
Dec 2023
40.59
Dec 2024
50.81
Dec 2025
31.8
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.